The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 23, 2022
Filed:
Oct. 14, 2016
Applicant:
Servier Pharmaceuticals Llc, Boston, MA (US);
Inventor:
Samuel V. Agresta, Lexington, MA (US);
Assignee:
SERVIER PHARMACEUTICALS LLC, Boston, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/444 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); C07H 19/09 (2006.01); C07H 15/252 (2006.01); C07D 403/14 (2006.01); A61P 35/02 (2006.01); A61K 31/136 (2006.01); A61K 31/7048 (2006.01);
U.S. Cl.
CPC ...
A61K 31/444 (2013.01); A61K 31/136 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7068 (2013.01); A61P 35/02 (2018.01); C07D 403/14 (2013.01); C07H 15/252 (2013.01); C07H 19/09 (2013.01);
Abstract
Provided are methods and compositions for treating acute myelogenous leukemia (AML) in patients carrying an IDH1 mutation using an inhibitor of a mutant IDH1 enzyme, (S)—N—((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide in combination with cytarabine and doxorubicin or idarubicin as an induction therapy and either cytarabine or a combination of combination of mitoxantrone and etoposide as consolidation therapy.